Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Galena Biopharma Inc.

www.galenabiopharma.com

Latest From Galena Biopharma Inc.

Deals Shaping The Medical Industry, September 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in August 2017.

Deals Medical Device

Finance Watch: 2Q Brings Cost Cuts, Strategic Reviews For Many Biotechs

Peregrine, Ardelyx, Egalet and others reduced expenses and sought alternatives in the second quarter. Also, cell and gene therapy investment rises, FibroGen priced a $326m offering and Unity increased its Series B by $35m.

Financing Business Strategies

Deal Watch: GSK Declines Option As Ionis' Inotersen Nears Finish Line

Ionis will file polyneuropathy candidate in US and EU on its own, while GSK de-emphasizes rare diseases. Aclaris buys Confluence in earn-out-heavy deal, and Galena undertakes reverse merger with Sellas.

Deals M & A

Finance Watch Public Company Edition: Akcea, Kala Launch IPOs While FOPOs Keep Busy Pace

Kala follows July's first biopharma IPO from Ionis spinout Akcea into the stock market. Amicus, Arena and othera go high with major offerings, while Inovio and Regulus go low. Also, Galena, Neothetics provide updates on their hunts for "strategic alternatives."

Financing Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • RXi Pharmaceuticals Corp.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Galena Biopharma Inc.
  • Senior Management
  • Stephen F Ghiglieri, Interim CEO
    Bijan Nejadnik, MD, EVP, CMO
    John T Burns, VP, Fin.
  • Contact Info
  • Galena Biopharma Inc.
    Phone: (925) 498-7700
    2000 Crow Canyon Pl.
    Ste. 380
    San Ramon, CA 94583
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register